Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 464Melanoma 300Squamous Cell Carcinoma of Head and Neck 234Parkinson Disease 4, Autosomal Dominant Lewy Body 189Neoplasms 185Triple Negative Breast Neoplasms 163Breast Neoplasms 162Neoplasm Metastasis 157Lung Neoplasms 147Colorectal Neoplasms 142Carcinoma, Renal Cell 132Head and Neck Neoplasms 123Stomach Neoplasms 104Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 81Pancreatic Neoplasms 81Endometrial Neoplasms 74Carcinoma, Hepatocellular 74Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 49Sarcoma 43Carcinoma 42Glioblastoma 40Small Cell Lung Carcinoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Cholangiocarcinoma 35

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Cyclophosphamide 3pembrolizumab 1fludarabine 1Vincristine 1Prednisone 1Interleukin-21 1Etoposide 1Doxorubicin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Experimental × pembrolizumab × Clear all
NCT05296772 2023-09-06

Phase 1 First-in-human Study of JS014

Anwita Biosciences

Phase 1 Unknown
60 enrolled
Lymphoid

Lymphoma, Neoplasms, Neoplasms, Experimental

Data powered by HemOnc (CC BY 4.0) Colophon âš¡